SVVYGLR
SVVYGLR is an osteopontin-derived peptide. SVVYGLR can promote the differentiation of fibroblasts into myofibroblast-like cells and promote the production of type III collagen by cardiac fibroblasts. SVVYGLR can activate the adhesion, migration and tubule formation of endothelial cells in vitro. SVVYGLR promotes angiogenesis and wound healing and promotes the migration of dermal fibroblasts and keratinocytes. SVVYGLR can be used for research related to angiogenesis, dermal wounds and bone regeneration.
For research use only. We do not sell to patients.
- CAS No.: 292851-89-9
- Formula: C36H60N10O10
- Molecular Weight:792.92
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
SVVYGLR (0.02 μg/mL) activates adhesion, migration, and tube formation by endothelial cells in vitro[1].
SVVYGLR (0.01-100 μg/mL; 2 h coating, 30 min cell incubation) enhances adhesion of hMSCs, hPLFs, hGFs, and HUVECs in a concentration-dependent manner, with the strongest effect at 100 μg/mL[2].
SVVYGLR (1-1000 ng/mL; continuous culture with medium renewal every other day, measured on day 6) enhances proliferation of hMSCs, HUVECs, and hPLFs (but not hGFs) in a concentration-dependent manner, with the strongest effect at 100 ng/mL on day 6[2].
SVVYGLR (10-1000 ng/mL; 5 days for RAW264.7 cells, 10 days for BMMs) suppresses osteoclastogenesis in RAW264.7 cells and BMMs, with significant inhibition at 100 ng/mL[2].
SVVYGLR (100 ng/mL; 24, 72, 96 h) suppresses RANKL-induced NFAT activity in pNFAT/Luc-RAW264.7 cells at 100 ng/mL[2].
SVVYGLR (100 ng/mL; 3, 5 days) downregulates expression of osteoclastogenic marker genes (calcitonin receptor, cathepsin K, TRAP) and integrin α9 in RANKL-stimulated RAW264.7 cells at 100 ng/mL[2].
SVVYGLR (10 ng/mL; 36 h) significantly accelerates the migration of rat dermal fibroblasts (RDFs) into scratch wound areas at 36 h[3].
SVVYGLR (10 ng/mL; 10 h) significantly accelerates the migration of human epithelial keratinocytes (HEKa) into scratch wound areas at 10 h[3].
SVVYGLR (10 ng/mL; 3 h) significantly enhances the migratory activity of rat dermal fibroblasts (RDFs) and human epithelial keratinocytes (HEKa) in a 3-hour Chemotaxicell migration assay[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:hMSCs, hPLFs, hGFs, HUVECs
-
Concentration:1-1000 ng/mL
-
Incubation Time:6 days
-
Result:Enhanced proliferation of hMSCs 1.4-fold, HUVECs 1.2-fold, and hPLFs 1.1-fold at 100 ng/ml on day 6 in a concentration-dependent manner. Did not affect hGF proliferation.
-
Cell Line:RAW264.7 cells
-
Concentration:100 ng/mL
-
Incubation Time:3, 5 days
-
Result:Decreased mRNA expression of calcitonin receptor, cathepsin K, TRAP, and integrin α9 in RANKL-stimulated cells relative to RANKL-only controls.
-
Cell Line:Rat dermal fibroblasts (RDFs)
-
Concentration:10 ng/mL
-
Incubation Time:0, 12, 24, 36 h
-
Result:Significantly accelerated migration into the scratch wound area at 36 h compared with untreated controls and scrambled SV peptide (rSV)-treated groups.
-
Cell Line:Human epithelial keratinocytes (HEKa)
-
Concentration:10 ng/mL
-
Incubation Time:0, 5, 10 h
-
Result:Significantly accelerated migration into the scratch wound area at 10 h compared with untreated controls and rSV-treated groups.
-
Cell Line:Rat dermal fibroblasts (RDFs) and Human epithelial keratinocytes (HEKa)
-
Concentration:10 ng/mL
-
Incubation Time:3 h
-
Result:Significantly enhanced migratory activity compared with untreated controls and rSV-treated groups.
-
Cell Line:Rat dermal fibroblasts (RDFs) and human epithelial keratinocytes (HEKa)
-
Concentration:10 ng/mL
-
Incubation Time:24, 48, 72, 96 h
-
Result:Showed no significant differences in proliferation compared with rSV-treated and untreated controls over 24-96 h.
In Vivo
SVVYGLR (10 µg; implanted via collagen sponge; single administration at the time of defect creation) suppresses osteoclast numbers in bone defects at 3 weeks and enhances collagen sponge resorption and compact bone formation by 5 weeks in a rat calvarial defect model[2].
SVVYGLR (12.5 μg/gel; topical via Medgel; single application at wound creation) promotes dermal wound healing by stimulating fibroblast migration, myofibroblastic differentiation of fibroblasts, and angiogenesis in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cAnNCrj (6-week-old female)[1]
-
Dosage:0.02 µg/mL
-
Administration:Implanted via diffusion chamber; 5 days
-
Result:Achieved a mean angiogenesis grade of 2.00; induced spiral and immature blood vessels; reached an angiogenic level approximately the same as that of vascular endothelial growth factor (VEGF).
-
Animal Model:Sprague-Dawley (male, 12-week-old, artificial bone defect model)[2]
-
Dosage:10 µg
-
Administration:implanted via collagen sponge; single administration at the time of defect creation
-
Result:Reduced number of TRAP-positive osteoclasts in bone defect area significantly compared to controls at 3 weeks post-operation; Decreased area of remaining collagen sponge significantly compared to controls at 5 weeks post-operation; Induced new bone formation extending to the periosteal surface (with compact bone morphology and cement lines) surrounding the sponge graft at 5 weeks post-operation。
-
Animal Model:Sprague-Dawley (male, 8-week-old, full-thickness 5-mm skin wound model)[3]
-
Dosage:12.5 μg/gel
-
Administration:topical via Medgel; single application at wound creation
-
Result:Accelerated wound closure compared to control and PBS groups (significant at days 6 and 8); Increased migration of HSP-47-positive fibroblasts to the wound area at day 4; Significantly enhanced number of α-SMA-positive myofibroblasts in the wound area at day 14; Marked increase in von Willebrand factor-positive neomicrovessels at day 7.
Chemical Information
-
CAS No. 292851-89-9
-
Molecular Weight 792.92
-
Formula C36H60N10O10
-
Sequence
Ser-Val-Val-Tyr-Gly-Leu-Arg
-
Sequence Shortening
SVVYGLR
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Cell-Exclusion Zone Migration Assay
The Cell-Exclusion Zone (CEZ) migration assay is an in vitro 2D cell migration method in which a defined cell-free area is created using removable physical barriers such as silicone stoppers, allowing cells to be seeded around the barrier and subsequently migrate into the cleared zone after barrier removal. This approach enables quantification of collective cell migration by monitoring repopulation of the initially cell-free region over time using microscopy-based imaging. Compared with scratch-based wound healing assays, barrier-based exclusion methods are designed to avoid mechanical damage to the extracellular matrix and reduce injury-induced effects on boundary cells, thereby improving interpretability of migration behavior in vitro. The assay readout is typically the progressive reduction in the cell-free area or the number of cells invading the exclusion zone, reflecting coordinated cell motility relevant to physiological processes such as wound healing, epithelial repair, and ca
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
Purity & Documentation
References
[1]. Hamada Y, et al. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Dent Mater J. 2004;23(4):650-655. [Content Brief]
[2]. Egusa H, et al. Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts. Biomaterials. 2009;30(27):4676-4686. [Content Brief]
[3]. Uchinaka A, et al. Evaluation of dermal wound healing activity of synthetic peptide SVVYGLR. Biochem Biophys Res Commun. 2017;491(3):714-720. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)